Canada Markets close in 1 hr 55 mins

Resverlogix Corp. (RVX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.1700-0.0200 (-10.53%)
As of 01:53PM EST. Market open.
Full screen
Loading interactive chart...
  • GlobeNewswire

    InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

    VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s future development related to COVID-19, will focus on the prevention and treatment of Post COVID-19 Conditions. The company’s new focus on patients with Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients, reflects the compelling opportunity for apabet

  • GlobeNewswire

    Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

    CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19 will focus on the prevention and treatment of Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients, reflecting the compelling opportunity for apabetalone to benefit PCC patients and guidance from the US Food and Drug Administration (FDA). A rece

  • GlobeNewswire

    Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

    CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse Cardiovascular Events with the BET Protein Inhibitor Apabetalone in Patients with Recent Acute Coronary Syndrome, Type 2 Diabetes, and Moderate to High Likelihood of Non-Alcoholic Fatty Liver Disease” in the American Journal of Preventive Cardiology. The article presents a post-hoc analysis of BETonMACE data